title: Complications and antireflux medication use after antireflux surgery.
abstract: OBJECTIVE
  Although antireflux surgery is increasingly common, few studies have assessed the associated complications and health care use after surgery. The aim of this study was to estimate postoperative complications and continued use of antireflux medications and to identify predictors of complications.
  
  
  METHODS
  Through a review of the Department of Veterans Affairs administrative databases, all patients undergoing antireflux surgery from October 1, 1990, through January 29, 2001, were identified. Of 3367 patients identified, 222 were excluded as a result of a diagnosis of esophageal cancer, achalasia, or because there was no diagnosis related to gastroesophageal reflux disease. Medication use was determined for 2406 patients who had a minimum of 1 year of follow-up, including 1 or more outpatient visits at least 6 months after surgery and during the time when national pharmacy records were available.
  
  
  RESULTS
  Dysphagia was recorded in 19.4%, dilation was performed in 6.4%, and a repeat antireflux surgery was performed in 2.3%. The surgical mortality rate was .8%. Prescriptions were dispensed repeatedly for H2 receptor antagonists in 23.8%, proton pump inhibitors in 34.3%, and promotility agents in 9.2% of patients. Overall, 49.8% of patients received at least 3 prescriptions for one of these medications.
  
  
  CONCLUSIONS
  A moderate proportion of patients undergoing antireflux surgeries experienced complications and approximately 50% of patients received multiple prescriptions for antireflux medications at a median of 5 years of follow-up evaluation. Therefore, before surgery is performed, patients considering surgery should be counseled fully about the risk for complications and the likelihood of continued antireflux medication use.
authors.affiliation: Northwest Health Services Research and Development Center of Excellence, VA Puget Sound Health Care System, Seattle, Washington 98108-1597, USA. jason.dominitz@va.gov
authors.forename: Jason A
authors.initials: JA
authors.lastname: Dominitz
authors.forename: Christopher A
authors.initials: CA
authors.lastname: Dire
authors.forename: Kevin G
authors.initials: KG
authors.lastname: Billingsley
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Todd-Stenberg
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000863:Antacids / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D018662:Fundoplication / Q000009:adverse effects*; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000601:surgery*; D006635:Histamine H2 Antagonists / Q000008:administration & dosage*; D006787:Hospitals, Veterans; D006801:Humans; D008297:Male; D008875:Middle Aged; D054328:Proton Pump Inhibitors; D017494:Proton Pumps / Q000008:administration & dosage*; D012189:Retrospective Studies; D014481:United States
chemical_list: D000863:Antacids; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors; D017494:Proton Pumps